ArticleFrontiers in oncology2025
Differentiation of early-stage tumors from benign lesions manifesting as pure ground-glass nodule: a clinical prediction study based on AI-derived quantitative parameters.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of radiological imaging in differentiating malignant and benign pulmonary nodules: a retrospective study.BMC medical imaging · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Differentiating between benign and malignant pure ground-glass nodule (pGGN) is of great clinical significance. The aim of our study was to evaluate whether AI-derived quantitative parameters could predict benignity versus early-stage tumors manifesting as pGGN. Methods: A total of 1,538 patients with pGGN detected by chest CT at different campuses of our hospital from May 2013 to December 2023 were retrospectively analyzed. This included CT and clinical data, as well as AI-derived quantitative parameters. All patients were randomly divided into a training group (n=893), an internal validation group (n=382), and an external validation group (n=263). Hazard factors for early-stage tumors were identified using univariate analysis and multivariate logistic regression analysis. Independent risk factors were then screened, and a prediction nomogram was constructed to maximize predictive efficacy and clinical application value. The performance of the nomogram was evaluated using ROC curves and calibration curves, while decision curve analysis (DCA) was used to assess the net benefit prediction threshold. Results: The final logistic model included nine independent predictors (age, location, minimum CT value, standard deviation, kurtosis, compactness, energy, costopleural distance, and volume) and was developed into a user-friendly nomogram. The AUCs of the ROC curves in the training, internal validation, and external validation cohorts were 0.696 (95% CI: 0.638-0.754), 0.627 (95% CI: 0.533-0.722), and 0.672 (95% CI: 0.543-0.801), respectively. The calibration plot demonstrated a good correlation between observed and predicted values, and the nomogram remained valid in the validation cohort. DCA showed that the model's predictive performance was acceptable, providing substantial net benefit for clinical application. Conclusions: The clinical prediction nomogram, based on AI-derived quantitative parameters, visually displays an overall score to differentiate benign lesions from early-stage tumors manifesting as pGGN. This nomogram may serve as a convenient screening tool for clinical use and provides a reference for formulating individualized follow-up and treatment plans for patients with pGGN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.